From this analysis of the role of the TFEB pathway in breast cancer chemoresistance, we reveal evidence that the increased expressions of TFEB and Beclin-1 are associated with a shorter survival period in patients suffering from invasive breast cancer who undergo chemotherapy. This evidence concerns the gene BECN1 and breast cancer.